Development

Amgen’s dazodalibep meets Phase III endpoint in systemic Sjögren’s disease

Amgen’s dazodalibep meets Phase III endpoint in systemic Sjögren’s disease

Amgen's (Nasdaq: AMGN) dazodalibep, a CD40 ligand (CD40L) antagonist fusion protein, met its primary endpoint in a Phase III trial of systemic Sjögren's disease, delivering statistically significant and clinically meaningful improvement in disease activity at Week 48. Amgen reported the topline results on September 22, 2026, and said detailed data will be presented at an upcoming medical meeting.

The OASIZ 301 study enrolled approximately 621 adults with moderate-to-severe systemic Sjögren's disease, defined by a EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score of 5 or above. The primary endpoint was change from baseline in ESSDAI at Week 48. Amgen said improvements were observed as early as Week 4 and were sustained through Week 48. No numerical results — mean changes, hazard ratios, or p-values — were disclosed in the topline release.

Dazodalibep blocks the CD40L–CD40 co-stimulatory interaction between T cells and B cells, disrupting the upstream immune activation that drives Sjögren's disease pathology. This mechanism distinguishes it from pipeline competitors targeting downstream B cell biology: Novartis's ianalumab depletes B cells via BAFF-R blockade, and Johnson & Johnson's nipocalimab reduces circulating IgG autoantibodies by inhibiting the neonatal Fc receptor (FcRn). Novartis received FDA Breakthrough Therapy Designation for ianalumab in Sjögren's disease in January 2026 and has been reported to be targeting a US launch in the second half of 2026, making it the most advanced competitor on a regulatory timeline. China-based RemeGen's telitacicept, a dual BAFF/APRIL inhibitor, received China NMPA approval for Sjögren's disease in June 2026, but holds no FDA or EMA approval in this indication.

The only currently approved therapies for Sjögren's disease — pilocarpine and cevimeline — are oral muscarinic agonists that address dry mouth symptoms and have no effect on systemic disease activity.

The AllSci BriefFree, systematic R&D and deal news. Daily.

The most common adverse events in OASIZ 301 — reported at 5% or greater incidence and at a higher rate than placebo — were nasopharyngitis, urinary tract infection, hypertension, and infusion-related reactions, which Amgen described as generally mild to moderate. Discontinuations due to adverse events occurred at a low rate and were balanced across treatment groups. No imbalance in thromboembolic events or opportunistic infections was observed.

Dazodalibep is simultaneously being evaluated in OASIZ 303, a Phase III study in patients with high symptom burden and low systemic disease activity, with completion expected in Q4 2026. A long-term extension study, OASIZ 304, is also enrolling eligible participants from both Phase III trials. Amgen has not disclosed a regulatory filing timeline. OASIZ 303, which evaluates patients with high symptom burden and low systemic disease activity, is expected to complete in Q4 2026.


Access the AllSci platform to explore the science behind the news.


Spot something wrong? Report an issue with this article